Quick Strip Sleep
Natural health product licensed in Canada
- Other names
- Bodhi Health Inc. Sleep
- Licence holder
- Rapid Dose Therapeutics Inc.
- NPN or DIN-HM
- 80085610
- Status
- Active licence
- Licence date
- 29 May 2018
- Revision date
- 15 January 2026
- Form
- Pellicule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| N-acétyl-5-méthoxytryptamine Source : Mélatonine | 5 milligramme | Not calculated |
Non-medicinal ingredients
Glycérine, Saccharinate de sodium, Bleu FD&C n° 1, Menthol, Acésulfame potassium, Maltodextrine, Saveur, D-Mannitol, Hypromellose, Copolymère d'acide méthacrylique et d'acrylate d'éthyle, Sucralose, Jaune FD&C No. 5, Eau purifiée, Hydroxyde de sodium, Povidone, Poly(sorbate) 80
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Pellicule | 1 Tous les jours |
Uses authorised in Canada
Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule, e.g. shift-work and jet lag. Helps to reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people with delayed sleep phase disorder. Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Mild gastrointestinal symptoms (nausea, vomiting, or cramping) have been known to occur in which case, discontinue use. Rare allergic reactions have been known to occur in which case, discontinue use.
- Précautions et mises en garde
Consumption with alcohol, other medications or natural health products with sedative properties is not recommended. If you are taking one of the following medications, consult a health care practitioner prior to use: anticoagulant, anticonvulsant, blood pressure medications, immunosuppressive medications, sedative, hypnotic or psychotropic medications, or steroids. If you have one of the following conditions, consult a health care practitioner prior to use: asthma, cardiovascular disease, chronic kidney disease, depression, diabetes or hypoglycaemia, hormonal disorder, immune system disease, liver disease, migraine, or seizure disorders. If symptoms persist continuously for more than 4 weeks (chronic insomnia), consult your health care practitioner.
- Contre-indications
If you are pregnant or breastfeeding, do not use this product.
Source
Official Health Canada record, licence 80085610
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.